この専門家をプロジェクトに採用したいですか? 見積もりを依頼 無料で。
プロフィール詳細
Eslam M.に依頼
Egypt
Freelance researcher interested in medicine & systematic review & meta-analysis & writing with 2+ years of experience
プロフィール概要
専門分野
サービス
職務経験
Student
Alexandria faculty of medicine
9月 2022 - 1月 2023
学歴
Bachelor degree in medicine and surgery
Alexandria Faculty of Medicine
9月 2017 - 現在
認定資格
- 認定資格の詳細は未入力です。
出版物
JOURNAL ARTICLE
Mohamed Mohamed Belal, Asmaa Reda Youssef, Hany Baker, Nessreen Awaad Elalaky, Ahmed Atef Marey, Muhammed Adel Quaisy, Eslam Mohammed Rabea (2023). Effect of Ramadan fasting on thyroid functions in hypothyroid patients taking levothyroxine: a systematic review and meta-analysis . Irish Journal of Medical Science (1971 -).
Rabea Eslam Mohammed, Belal Mohamed Mohamed, Youssef Asmaa Reda, Elalaky Nessreen Awaad, Hany Baker, Muhammed Quaisy Muhammed Adel(2023). Thyroid hormone replacement during Ramadan fasting is a real challenge to hypothyroid patients. A systematic review and meta-analysis . Endocrine Abstracts. Bioscientifica
Kirellos Said Abbas, Eslam Mohammed Rabea, Basel Abdelazeem(2022). Authors’ reply to the letter to editor “Does Ramadan Fasting Affect the Therapeutic and Clinical Outcomes of Warfarin?” . European Journal of Clinical Pharmacology. 78. (6). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1055--1056. Springer Science and Business Media {LLC}
Eslam Mohammed Rabea, Kirellos Said Abbas, Dina M. Awad, Nancy H. Elgoweini, Amro Ahmed El-Sakka, Nada H. Mahmoud, Basel Abdelazeem(2022). Does ramadan fasting affect the therapeutic and clinical outcomes of warfarin? a systematic review and meta-analysis . European Journal of Clinical Pharmacology. 78. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 755--763. Springer Science and Business Media {LLC}
REVIEW
Eslam Mohammed Rabea, Mohamed Mohamed Belal, Anas Zakarya Nourelden, Ashraf Hassan Elbanna, Mahmoud Ahmed Khalifa, Nada H. Mahmoud, Mohamed Sayed Zaazouee(2023). A systematic review and meta-analysis of extended interval dosing (EID) vs. standard-interval dosing (SID) of Natalizumab for multiple sclerosis patients. (P8-3.005) . Tuesday, April 25. Lippincott Williams {\&} Wilkins